Sonoma Bio Raises $265m To Test T-regs In Autoimmune Diseases

First Indication Is RA, But IBD Is Another Opportunity

04 Aug 2021

The company will determine whether a single administration of autologous regulatory T-cells (Tregs) can reset and restore immune tolerance in autoimmune, inflammatory and neuroinflammatory diseases.

Young woman with rheumatoid arthritis deformed fingers — Sonoma Bio's T-reg therapies may offer a polypharmacy approach to treating rheumatoid arthritis and other autoimmune diseases • Source: Alamy

Sonoma Bio Raises $265m To Test T-regs In Autoimmune Diseases

First Indication Is RA, But IBD Is Another Opportunity

More from Financing

More from Business